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http://dx.dSerum IgG Responses against Aspergillus Proteins
before Hematopoietic Stem Cell Transplantation or
Chemotherapy Identify Patients Who Develop
Invasive Aspergillosis
Chen Du,1 John R. Wingard,2 Shaoji Cheng,1 M. Hong Nguyen,1 Cornelius J. Clancy1,3The ability to identify patients at particularly low risk for invasive aspergillosis (IA) would facilitate more ef-
ficient targeting of antifungal prophylaxis. We measured baseline serum immunoglobulin responses against 6
purified recombinant Aspergillus fumigatus proteins before hematopoietic stem cell transplantation (HSCT)
or chemotherapy in 73 subjects, including 19 patients who subsequently developed proven or probable IA
and 54 uninfected controls. We also assessed responses at the time of IA diagnosis and 4 weeks later (acute
and convalescent sera, respectively). Baseline IgG responses against enolase, Ahp1, Hsp90, Crf1, and Cdc37
were significantly higher in the patients with IA compared with controls (P \ .05). Cutoff concen-
trations identified by reveiver-operating characteristic curve analysis were 67%-84% sensitive and 52%-
67% specific. In a population with a 15% likelihood of developing IA, positive and negative predictive values
would be 22%-26% and 92%-95%, respectively. Positive IgG responses against Hsp90, Pep2, Crf1, and Cdc37
were specifically associated with early-onset IA (\40 days) rather than late-onset IA (P # .009). Increased
IgG concentrations against Hsp90, Pep2, and Crf1 in convalescent sera versus baseline sera were more likely
in the patients with IA who survived (P # .01). IgG responses in acute sera were not correlated with out-
comes, and IgM and IgA responses did not differ in baseline, acute, or convalescent sera between the patients
and controls. In conclusion, baseline IgG responses against Aspergillus proteins may be useful screening tests
for patients at low risk for IA. Our data suggest that some patients with IA have significant colonization or
ongoing Aspergillus infections before immunosuppression. As such, IA may reflect unique predispositions to
infection and/or progression from endogenous sources.
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Approximately 15%-20% of hematopoietic stem
cell transplantation (HSCT) recipients and patients
receiving chemotherapy for hematologic malignancies
develop invasive aspergillosis (IA) [1-4]. IA can develop
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immunosuppression are risk factors for early-onset
IA, whereas such factors as steroid use and chronic
graft-versus-host disease are major risks for late-
onset IA [2,3]. Case fatality rates for both early and
late IA are as high as 50%-90% despite antifungal
therapy [1-5]. The prompt treatment of IA improves
survival [6-8], but timely and accurate diagnosis is
often difficult.
Given the severity of IA and the challenges of es-
tablishing a definite diagnosis, prophylactic antifungal
therapy is often administered to patients considered at
high risk for IA [9,10]. Even in the highest-risk popu-
lations, however, preventive strategies are limited by
the low prevalence of the disease, which dictates that
large numbers of patients must be exposed to an inter-
vention to prevent a small number of cases [6,7]. In
these scenarios, economic costs and the risks of drug
toxicity, untoward drug–drug interactions, and1927
1928 Biol Blood Marrow Transplant 18:1927-1934, 2012C. Du et al.emergence of drug resistance may outweigh the
benefits of preventing IA. Not surprisingly, there is
great interest in devising methods of identifying
subgroups at particularly high risk for developing
IA. Screening tests that stratify patients before
transplantation or immunosuppression, such as
genetic testing for deficiencies in components of
innate immunity, are currently in development, but
none has yet been introduced to clinical practice
[11-14]. When developing screening strategies for
IA, it is important to recognize that the positive
predictive value (PPV) of any test, even one with
good sensitivity and specificity, will be limited by the
low prevalence of the disease. As such, it has been
suggested that the objective of screening should be to
maximize the negative predictive value (NPV) [6,7],
thereby reliably identifying low-risk patients who are
unlikely to develop IA.
Along these lines, an earlier study demonstrated
that measurements of serum IgG responses against As-
pergillus fumigatus catalase at the time of hospital ad-
mission for HSCT or treatment of a hematologic
malignancy were 78% sensitive and 74% specific in
identifying patients who later developed IA [15]. Based
on these figures, the anticipated NPV of baseline anti-
catalase IgG testing would be 95% in a population
with a 15% prevalence of IA and even higher in popu-
lations with a lower prevalence. These data suggest
that baseline antibody testing against A fumigatus pro-
teins may be a useful screening strategy for IA in rela-
tively high-risk populations. The primary objective of
the present study was to compare baseline IgG re-
sponses against purified recombinant A fumigatus pro-
teins in the sera of HSCT recipients and patients with
hematologic malignancy who subsequently developed
IA and those who did not (negative controls). We also
sought to correlate serum IgG responses with the out-
comes of IA.MATERIALS AND METHODS
Patient Population and Definitions
Patients with acute leukemia undergoingHSCTor
receiving chemotherapy who consented to inclusion in
our Mycology Research Unit repository were eligible
for this study, which was approved by and performed
according to guidelines of the Institutional Review
Board at theUniversity of Florida. Baseline blood sam-
ples were obtained before HSCT or receipt of chemo-
therapy. These patients were followed prospectively
for a minimum of 1 year or until death. In the patients
who developed IA, blood samples were also collected
on the day of diagnosis (acute serum) and 4-6 weeks
later (convalescent serum). Surviving patients were fol-
lowed for at least 6 weeks after the diagnosis of IA [16].
IA was classified as proven or probable using the Euro-pean Organization for Research and Treatment of
Cancer–Mycoses Study Group criteria [17]. Early-
onset and late-onset IA were defined as cases
developing within 40 days of HSCT and after 40 days
of HSCT, respectively [3]. Patients receiving chemo-
therapy who developed IA were considered to have
early-onset IA.Outcomes of IAwere defined according
EuropeanOrganization forResearch andTreatment of
Cancer and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group (EORTC-
MSG) criteria [18].
Determination of Immunoglobulin Responses to
Aspergillus Proteins
We performed ELISA against 6 recombinant pro-
teins. Five proteins (enolase, Ahp1, Hsp90, Pep2, and
Crf1) were chosen because they were identified by
a study that screened a cDNA library with sera from
rabbits experimentally infected with A fumigatus [19].
Each of these proteins has been shown to react with an-
tibodies in human sera. Enolase, Ahp1, and Crf1 are
known allergens that elicit IgE responses in patients
with allergic aspergillosis [20-23]. Anti-Hsp90 and
anti-Pep2 antibodies are found in the sera of patients
with various types of aspergillosis [15,24,25]. Of note,
Candida albicans enolase and Hsp90 induce protective
immune responses against systemic candidiasis in
both mice and humans, respectively [26-31].
Moreover, human recombinant monoclonal antibody
against an Hsp90 epitope was shown in a clinical trial
to improve the efficacy of lipid formulation
amphotericin B against invasive candidiasis [28]. Fi-
nally, we selected Cdc37 as the sixth protein, because
it is an Hsp90 co-chaperone (http://www.ncbi.nlm.
nih.gov/gene/8048582), which was reactive with anti-
bodies in human sera with IA in a pilot screen.
Expression and Purification of Aspergillus
Recombinant Proteins
A fumigatus (AF 237) was maintained on BBLMalt
Agar medium (BD Diagnostic Systems, Sparks, MD).
For RNA isolation, A fumigatus was first cultured on
a BBL Malt Agar medium slant for 5 days. A conidial
suspension was then prepared by washing the surface
with PBS including 0.05%Tween 20 and then filtering
through CalbiochemMiracloth (EMDMillipore, Bill-
erica, MA) to remove debris and hyphae. A suspension
of 1  108 spores/mL of A fumigatus was inoculated in
100 mL of YG medium (0.5% yeast extract and 2%
glucose), which was incubated subsequently at 37C.
After 16 hours, hyphae were harvested by filtration
through #1 Whatman filter paper, quick-frozen in
liquid nitrogen, and disrupted by grinding. Total
RNA from mycelia was extracted using an Ambion
RNA Extraction Kit for Yeast (Life Technologies,
Carlsbad, CA).
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Biol Blood Marrow Transplant 18:1927-1934, 2012 1929Antibody Response in Patients with Invasive AspergillosisSynthesis of first-strand cDNA was performed
with 1 mg of total RNA using the Improm-II Re-
verse-Transcription System (Promega, Madison,
WI). Then 2 mL of cDNA from the reverse-
transcription reactions were used for subsequent
PCR (Phusion Flash High-Fidelity PCR Master Mix;
New England BioLabs, Ipswich, MA) with gene-
specific primers to obtain the full-length or partial
cDNA (Table 1). The final primer concentration was
0.5 mM.Cycling conditions for 2-step PCRwere initial
denaturation at 98C for 10 seconds, denaturation at
98C for 1 second, extension at 72C for 15 seconds/
kb; and final extension at 72C for 5 minutes.
Gel-purified PCR products (A fumigatus
cDNA encoding each protein) were cloned into
pET-32 Ek/LIC vector (Novagen; EMD Millipore),
which was prepared for high-level expression of poly-
peptides. Fusion proteins contained a cleavable His-
Tag for detection and purification. The annealed
LIC vector and insert were transformed into compe-
tent Escherichia coli BL21 (DE3) (Novagen), and inserts
were confirmed by colony-PCR and sequencing. An
Ahp1 (168-aa peptide) expression strain was kindly
provided by Dr. Utz Reichard [19]. Isopropyl b-D-1-
thiogalactopyranoside (1 mM) was used to induce the
maximum expression of desired proteins in E. coli.
Cells from overnight liquid culture were harvested
by centrifugation, and the cell pellet was suspended
at room temperature in BugBuster Protein Extraction
Reagent containing Benzonase Nuclease (125 U/g cell
paste; Novagen). After a 20-minute incubation at room
temperature, the insoluble cell debris was removed by
centrifugation. The pellet was saved for inclusion body
extraction. The remaining soluble extract was sub-
jected to subsequent purification with a His-Bind Pu-
rification Kit (Novagen). For Cdc37, Hsp90, and
Pep2, pilot experiments showed that most of the ex-
pressed protein was included in the insoluble inclusion
body. Inclusion body purification was performed by
incubation with 1 binding buffer containing 1 KU/
mL lysozyme and column purification under denatur-
ing conditions (with 6 M urea included in the binding
buffer and elution buffer). The purity of the proteins
was determined by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis and Western blot analysis
with an antipolyhistidine monoclonal antibody.T
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All protein antigens were coated overnight at 4C
on ELISA plates (EIA/RIA plates; Corning, Corning,
NY) at a coating buffer concentration of 1 mg/mL. Af-
ter washing, the wells were filled with 300 mL of 10%
nonfat dry milk in PBS supplemented with 0.25%
Tween 20 (PBST). After a 2-hour incubation at
room temperature, patient serum diluted 1:100 in
PBST was added to each well. The plates were
1930 Biol Blood Marrow Transplant 18:1927-1934, 2012C. Du et al.incubated for 1 hour at 37C and then washed 4 times
with PBST. Secondary HRP-conjugated anti-IgG,
-IgM, or -IgA antibody (MP Biomedicals, Solon,
Ohio) was diluted 1:1000 and then added to each
well. After a 1-hour incubation, the plates were washed
three times with PBST and once with PBS, and then
developed with o-phenylenediamine. The developing
reaction was stopped with 1 M phosphoric acid. Opti-
cal densities were determined using a spectrophotome-
ter at 450 nm. Background was defined in wells coated
with the protein to which the secondary antibody was
added but the primary antibody was not. All serum
samples were tested in duplicate.
A standard curve was constructed using plates
coated with 100 mL of 1 mg/mL mouse anti-human
lambda antibody (Southern Biotech, Birmingham,
AL) and purified human IgG solution (concentrations
ranging from 10-1250 ng/mL; MP Biomedicals). A
standard curve was plotted as standard IgG concentra-
tion versus the corresponding mean optical density
value of triplicates. The concentrations of the putative
immunoglobulin-containing samples were then inter-
polated from the standard curve.
Statistical Analyses
Median and interquartile IgG, IgM, and IgA
concentrations against individual antigens were calcu-
lated, and differences were assessed using the Mann-
Whitney test; statistical significance was set at
P \ .05. Sensitivity and specificity were calculated
for antibodies against each antigen. Optimal cutoffs
were determined by receiver-operating characteristic
curve analyses. Positive and negative predictive values
were calculated based on an IA rate of 15%.RESULTS
Baseline Serum IgG Responses against
Recombinant A fumigatus Proteins
Seventy-three patients were enrolled, including 19
patients with IA and 54 uninfected controls. Sixteen of
the 19 patients with IA (84%) had undergone HSCT,
and the other 3 (16%) had received chemotherapy for
hematologic malignancy. The corresponding numbers
for the uninfected controls were 53 of 54 (98%) and 1
(2%). Among the patients with IA, 16 (84%) had inva-
sive pulmonary aspergillosis and 3 (16%) had dissem-
inated aspergillosis. The median time from HSCT to
IA was 26 days (range, 2-322 days). Thirteen patients
(68%) had early-onset IA. Eighteen of the 19 cases of
IA were caused by A fumigatus, and 1 case was caused
by A niger. All patients with IA and controls received
fluconazole as antifungal prophylaxis.
Baseline serum IgG, IgM, and IgA concentrations
were measured against purified recombinant enolase
and Ahp1 in all patients and controls immediately be-fore HSCT or institution of chemotherapy. Because of
a shortage of serum from 1 patient with late-onset IA,
immunoglobuilin concentrations against Hsp90,
Pep2, Crf1, and Cdc37 were determined for 18 pa-
tients and 54 controls.
There was significant intrasubject and intersubject
variability in baseline IgG concentrations among both
patients with IA and controls. In other words, the rel-
ative IgG concentrations in the serum of most subjects
were not uniform against the panel of recombinant
proteins. However, there was some correlation be-
tween responses against enolase, Ahp1, and Hsp90
(R2 5 0.84); Hsp90 and Pep2 (R2 5 0.86); and Crf1
and Cdc37 (R2 5 0.84).
Baseline IgG concentrations against enolase,
Ahp1, Hsp90, Crf1, and Cdc37 were significantly
higher in the patients with IA compared with controls
(Table 2). By receiver-operating characteristic curve
analysis, we assigned cutoff IgG concentrations that
best discriminated the patients with IA from controls
(data not shown). The sensitivities and specificities of
the cutoff concentrations in identifying patients who
subsequently developed IA are presented in Table 2.
Positive test results against enolase, Ahp1, Hsp90,
Crf1, and Cdc37 were significantly associated with
the development of IA.We also assessed combinations
of 2 or more proteins, but results were not superior to
those of the best proteins tested singly.
Baseline Serum IgG Responses among Patients
with Early-Onset and Late-Onset IA
Baseline IgG concentrations against enolase,
Hsp90, Pep2, Crf1, and Cdc37 were significantly
higher in patients with early-onset IA than in controls.
Baseline IgG concentrations were similar in patients
with late-onset IA and controls. In a direct comparison
of baseline sera in patients with early-onset IA and
those with late-onset IA, positive IgG responses
against Hsp90, Pep2, Crf1, and Cdc37 were specifi-
cally associated with early-onset disease (Table 2).
Indeed, 100% (13 of 13) of patients who developed
early-onset IA had a positive baseline IgG response
against at least 2 proteins from among Hsp90, Pep2,
Crf1, and Cdc37, compared with 20% (1 of 5) of
patients with late-onset IA (P5 .001). Positive baseline
IgG responses against at least 3 of these proteins were
positive in 85% (11 of 13) of patients with early-onset
IA and in 20% (1 of 5) of those with late-onset IA
(P 5 .002). Baseline IgG responses against enolase
and Ahp1 were similar in patients with early-onset
and late-onset disease.
Associations between Serum IgG Response and
Outcomes of IA
Serum was available from the time of diagnosis of
IA (acute serum) in 100% (19 of 19) of the patients
Table 2. IgG Responses against A fumigatus Proteins
Range, ng/mL
Enolase Ahp1 Hsp90 Pep2 Crf1 Cdc37
0-614.3 0-346.8 0-45.0 0-29.4 0-46.3 0-36.1
All patients
IA, median (IQR) 21.9 (11.0-91.6) 34.6 (0-58.9) 1.7 (0-5.8) 0.8 (0-2.6) 3.4 (0-6.9) 1.1 (0.1-2.7)
Controls, median (IQR) 0 (0-34.1) 0.9 (0-31.4) 0 (0-1.1) 0 (0-1.4) 0 (0-2.2) 0 (0-2.31)
P value .03 .04 .04 .11 .049 .046
Sensitivity 84% (16 of 19) 74% (14 of 19) 67% (12 of 18) 72% (13 of 18) 67% (12 of 18) 78% (14 of 18)
Specificity 56% (30 of 54) 59% (32 of 54) 67% (36 of 54) 56% (30 of 54) 65% (35 of 54) 52% (28 of 54)
Likelihood ratio 1.9 1.8 2 1.6 1.9 1.6
P value .003 .017 .02 .057 .03 .03
PPV, % 25 26 26 22 25 23
NPV, % 95 94 92 92 92 94
Anticipated negative baseline tests, % 50
Patients with early-onset IA
IA, median (IQR) 21.9 (12.5-98.3) 34.6 (2.0-53.1) 4.24 (1.4-6.6) 1.7 (0.3-3.3) 5.1 (1.8-8.2) 2.5 (0.4-2.8)
P value .04 .07 .0012 .009 .0005 .006
Sensitivity 85% (11 of 13) 77% (10 of 13) 85% (11 of 13) 92% (12 of 13) 92% (12 of 13) 100% (13 of 13)
Patients with late-onset IA
IA, median (IQR) 22.4 (8.2-77.0) 30.2 (0-84.9) 0 (0-0.3) 0 (0-0.6) 0 (0-0) 0 (0-0.4)
P value .22 .23 .20 .23 * .20
Sensitivity 83% (5 of 6) 67% (4 of 6) 20% (1 of 5) 20% (1 of 5) 0% (0 of 5) 20% (1 of 5)
P value 1.0 1.0 .02 .008 .0007 .002
Baseline serum IgG concentrations in the patient who developed disease due to A nigerwere higher than themedian concentrations in all patients with IA
against 5 proteins (Ahp1, Hsp90, Pep2, Crf1, and Cdc37) and virtually identical to the median against enolase (patient, 21.8 ng/mL; median, 23.1 ng/mL).
*Could not be calculated.
Biol Blood Marrow Transplant 18:1927-1934, 2012 1931Antibody Response in Patients with Invasive Aspergillosisand at 4 weeks after diagnosis (convalescent serum) in
68% (13 of 19) of patients. Similar to baseline, there
was significant intrasubject and intersubject variability
in IgG concentrations in acute and convalescent sera.
Unlike at baseline, however, acute serum IgG re-
sponses did not differ between patients with IA and
controls, and were not correlated with the time to on-
set of IA (data not shown). Overall, baseline and acute
serum IgG concentrations against any of the recombi-
nant proteins were not significantly different between
the 47% (9 of 19) of patients who lived and the 53%
(10 of 19) who died after the diagnosis of IA.
Among the patients with convalescent samples,
31% (4 of 13) lived and 69% (9 of 13) died. Patients
who lived after being diagnosed with IA were more
likely than patients who died, which demonstrated in-
creased serum IgG concentrations against Hsp90,
Pep2, and Crf1 in convalescent serum compared with
baseline (Table 3).
Serum IgM and IgA Responses against
Recombinant Proteins
There were no significant differences in IgM and
IgA responses in baseline, acute, or convalescent sera
between the patients with IA and controls.DISCUSSION
This study is most notable for 2 findings. First,
baseline serum IgG concentrations against recombi-
nant A fumigatus enolase, Hsp90, Pep2, Crf1, and
Cdc37 at the time of HSCT or chemotherapy for a he-matologic malignancy were significantly higher in pa-
tients who subsequently developed proven or probable
IA than in control patients who did not. In contrast,
baseline IgM or IgA responses were not correlated
with IA. Second, positive baseline IgG responses
against at least 2 proteins among a panel consisting
of Hsp90, Pep2, Crf1, and Cdc37 were specifically as-
sociated with early-onset rather than late-onset IA. By
capturing baseline anti-Aspergillus antibody responses,
our data provide a snapshot of the history of the host–
pathogen interaction at the critical stage immediately
before the onset of immunosuppression. This study
is important for both the insight that it provides into
the pathogenesis of IA and its potential implications
for clinical practice.
Our findings indicate that in at least some patients,
IA occurs in the context of an ongoing interaction be-
tween Aspergillus and the host immune system that an-
tedates HSCT or the administration of chemotherapy.
Along these lines, other studies have also reported ele-
vated baseline serum IgG responses against purified
recombinant A fumgiatus proteins in patients with IA.
In one study, approximately one-half of HSCT recip-
ients and patients with hematologic malignancy with
IA demonstrated high IgG titers against A fumigatus
catalase and dipeptidyl-peptidase VDDPV on hospital
admission [15]. In another study, 6 bonemarrow trans-
plant recipients with IA had positive baseline IgG
responses against Pep2 and 3 other proteins (superox-
ide dismutase, a metalloprotease, and a 94-kDa pro-
tein), although these responses were not compared
with those in controls [25]. The elevated baseline
IgG responses against recombinant proteins in those
Table 3. Serum IgG Responses in Convalescent Sera, Strati-
fied by Outcome
Recombinant
Protein
Percentage of Patients with Increased IgG in
Convalescent Sera (4 Weeks)
Lived Died P Values
Enolase 50 (2 of 4) 75 (6 of 8) .54
Ahp1 75 (3 of 4) 33 (3 of 9) .27
Hsp90 75 (3 of 4) 0 (0 of 9) .01
Crf1 75 (3 of 4) 0 (0 of 9) .01
Cdc37 75 (3 of 4) 33 (3 of 9) .3
Pep2 100 (4 of 4) 11 (1 of 9) .007
1932 Biol Blood Marrow Transplant 18:1927-1934, 2012C. Du et al.studies and ours suggest that some patients with IA
were colonized with Aspergillus or had unrecognized
invasive infections either in the past or up to the time
of HSCT or chemotherapy. Our IgM data imply that
the pathogen–host interaction was not initiated in
the period immediately before HSCT or chemother-
apy, but rather was more long-standing. These conclu-
sions have 2 important implications for pathogenesis.
In certain patients, episodes of colonization or unrec-
ognized infection may signal a particular susceptibility
to A fumigatus, such as may be seen with underlying
lung abnormalities or defects in innate immunity.
Moreover, in the face of ongoing colonization or infec-
tion, IA may reflect progression from endogenous
sources after the onset of profound immunosuppres-
sion.
The latter possibility is consistent with the obser-
vation that baseline IgG responses were predictive of
early-onset IA, but not of late-onset IA. Indeed, most
cases of late-onset IA are believed to be newly acquired
in the community after hospital discharge. Such acqui-
sition is in keeping with the generally accepted model
for the pathogenesis of IA in HSCT recipients and pa-
tients with hematologic malignancies, in whom disease
is attributed to the inhalation of a sufficient inoculum
of Aspergillus conidia by a susceptible host [32,33].
Clearly, de novo acquisition of IA occurs in the
hospital and community [34-40]. Even in outbreak
situations, however, only a minority of cases of IA
are conclusively linked to environmental strains
[34,41], suggesting that mechanisms of pathogenesis
in addition to acute inhalation may be relevant.
The major clinical implication of our findings is
that baseline antibody testing against A fumigatus pro-
teins may be useful as a screening test to identify pa-
tients at particularly low risk for developing IA. For
example, if baseline serum IgG concentrations against
enolase (the best performing of the proteins) were used
for screening a population with a disease prevalence of
15%, then the anticipated PPV would be only 25%
(Table 2); however, the NPV would be 95%. More-
over, 50% of the population would have a negative
baseline test and fall into a low-risk group (Table 2).
These values are similar to those anticipated for IgG
responses against catalase based on previously pub-lished sensitivity and specificity values; the NPV of
catalase also would be 95%, and 76% of patients would
test negative at baseline. In populations with lower dis-
ease prevalence, NPVs would improve, and more pa-
tients would test negative. Therefore, data from
separate studies suggest that IgG screening against
certain A fumigatus proteins has high NPV for IA
and would identify a significant number of low-risk
patients.
Of course, determinations of whether prophylactic
strategies built on such screening are worthwhile must
weigh the potential benefits and costs. Our data sug-
gest that benefits would include targeting antifungal
therapy toward a subgroup that includes the vast ma-
jority of patients who are most likely to develop IA,
while avoiding unnecessary antifungal exposure in
a large number of low-risk patients. The costs would
reflect the consequences of false-positive and false-
negative test results. To continue our example, base-
line anti-enolase testing of 1000 HSCT recipients in
the foregoing population would allow us to administer
prophylaxis to 125 patients who would be anticipated
to develop IA and avoid antifungal exposure in 475
who would not develop IA. At the same time, we would
fail to give prophylaxis to 25 patients with IA and give
prophylaxis to 375 patients who would not develop IA.
Patients in the latter group would incur unnecessary fi-
nancial expenses and face the possibility of untoward
events such as drug toxicity, deleterious drug–drug in-
teractions, and emergence of antifungal resistance or
selection of drug-resistant fungi.
Our small sample size limits our ability to draw de-
finitive conclusions about the convalescent antibody
data. Nevertheless, our findings indicate that increased
serum IgG responses against Hsp90, Pep2, and Crf1 at
week 4 compared with baseline were more common in
the patients with IA who lived than in those who died.
Several previous studies reported that absent or declin-
ing antibody responses against A fumigatus culture
filtrates, a 40-kDa antigen, and recombinant proteins
were associated with death from IA [25,42-44].
Based on these observations, it has been proposed
that increasing antibody titers at the end of
immunosuppression are indicative of recovery from
IA, whereas the absence of such responses suggests a
poor prognosis [15]. On the other hand, a recent
prospective study did not detect increases in anti-
Aspergillus antibody responses during the course of
IA, nor did antibody responses discriminate between
patients who clinically responded to antifungal therapy
and those who did not [45]. In the present study, it is
possible that increased IgG responses are simply
markers for other determinants of survival, such as
an improved overall state of health or a reconstituted
immune system. At the same time, antibody responses
against one or more of the proteins might have con-
tributed to the resolution of disease. In this regard, it
Biol Blood Marrow Transplant 18:1927-1934, 2012 1933Antibody Response in Patients with Invasive Aspergillosisis notable that studies in a Galleria mellonella (wax
moth) model showed that combination therapy with
anHsp90 inhibitor and an echinocandin rescued larvae
from A fumigatus infections [46].
Future studies are indicated to verify associations
between baseline IgG responses and the subsequent
development of IA, and to more conclusively establish
the sensitivity, specificity, and predictive values of such
testing. Given that the baseline data suggest that some
patients who develop IA had significant colonization
or ongoing Aspergillus infections at baseline, it will be
valuable to study antibody tests in conjunction with
detection assays such as serum galactomannan or poly-
merase chain reaction. In any future studies, it will be
important to establish that the utility of antibody test-
ing is not limited by interpatient and intrapatient var-
iability. If our baseline data are corroborated, then
standardized antibody assays should be developed
and validated. These assays would facilitate clinical tri-
als of preventive strategies built on serum IgG screen-
ing. Validation of the specific correlation between
baseline IgG responses and early-onset IA, for exam-
ple, would provide a rationale for antifungal prophy-
laxis during the first 2 months after HSCT or
high-risk chemotherapy. If future studies confirm
that convalescent responses against particular proteins
correlate with survival after IA, then the protective
roles of these responses should be investigated. Finally,
antibody testing of solid organ transplant recipients
and other populations at high risk for IA may provide
insight into unique mechanisms of pathogenesis and
identify additional diagnostic and therapeutic targets
and potential virulence factors. Along these lines, base-
line profiling of lung transplant recipients may be par-
ticularly interesting, given our previous report that
unrecognized IA and other invasive mold infections
in explanted lungs are associated with posttransplanta-
tion fungal infections and poor outcomes [47].ACKNOWLEDGMENTS
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